First international TNBC conference meeting report

Padmashree Rida^{1

2}, Angela Ogden¹, Ian O Ellis³, Zsuzsanna Varga⁴, Antonio C Wolff⁵, Tiffany A Traina^{6

7}, Christos Hatzis⁸, Julie R Palmer⁹, Christine B Ambrosone¹⁰, Brian D Lehmann¹¹, Rita Nanda¹², Valerie Montgomery Rice¹³, Otis W Brawley¹⁴, Mylin A Torres^{15

16}, Emad Rakha³, Ritu Aneja¹⁷

Affiliations

¹ Department of Biology, Georgia State University, Atlanta, GA, USA.
² Novazoi Theranostics, Rolling Hills Estates, CA, USA.
³ Department of Histopathology, Nottingham City Hospital NHS Trust, Nottingham University, Nottingham, UK.
⁴ Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland.
⁵ The Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.
⁶ Breast Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁷ Weill Cornell Medicine, New York, NY, USA.
⁸ Department of Medicine, Breast Medical Oncology, Yale School of Medicine, Yale University, New Haven, CT, USA.
⁹ Slone Epidemiology Center, Boston University, Boston, MA, USA.
¹⁰ Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
¹¹ Department of Biochemistry, Vanderbilt University, Nashville, TN, USA.
¹² Section of Hematology-Oncology, Department of Medicine, The University of Chicago, Chicago, IL, USA.
¹³ Morehouse School of Medicine, Atlanta, GA, USA.
¹⁴ American Cancer Society, Atlanta, GA, USA.
¹⁵ Department of Radiation Oncology, Emory University, Atlanta, GA, USA.
¹⁶ Glenn Family Breast Center, Winship Cancer Institute, Emory University, Atlanta, GA, USA.
¹⁷ Department of Biology, Georgia State University, Atlanta, GA, USA. raneja@gsu.edu.

PMID: 29417299
PMCID: PMC5955852
DOI: 10.1007/s10549-018-4692-3

First international TNBC conference meeting report

Padmashree Rida et al. Breast Cancer Res Treat. 2018 Jun.

. 2018 Jun;169(3):407-412.

doi: 10.1007/s10549-018-4692-3. Epub 2018 Feb 8.

Authors

Affiliations

¹ Department of Biology, Georgia State University, Atlanta, GA, USA.
² Novazoi Theranostics, Rolling Hills Estates, CA, USA.
³ Department of Histopathology, Nottingham City Hospital NHS Trust, Nottingham University, Nottingham, UK.
⁴ Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland.
⁵ The Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.
⁶ Breast Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁷ Weill Cornell Medicine, New York, NY, USA.
⁸ Department of Medicine, Breast Medical Oncology, Yale School of Medicine, Yale University, New Haven, CT, USA.
⁹ Slone Epidemiology Center, Boston University, Boston, MA, USA.
¹⁰ Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
¹¹ Department of Biochemistry, Vanderbilt University, Nashville, TN, USA.
¹² Section of Hematology-Oncology, Department of Medicine, The University of Chicago, Chicago, IL, USA.
¹³ Morehouse School of Medicine, Atlanta, GA, USA.
¹⁴ American Cancer Society, Atlanta, GA, USA.
¹⁵ Department of Radiation Oncology, Emory University, Atlanta, GA, USA.
¹⁶ Glenn Family Breast Center, Winship Cancer Institute, Emory University, Atlanta, GA, USA.
¹⁷ Department of Biology, Georgia State University, Atlanta, GA, USA. raneja@gsu.edu.

PMID: 29417299
PMCID: PMC5955852
DOI: 10.1007/s10549-018-4692-3

Abstract

Recently, Georgia State University's Centennial Hall was the premier location for the 2017 International Conference on Triple Negative Breast Cancer (TNBC): Illuminating Actionable Biology, which was held from Sept. 18 to 20, 2017, in Atlanta, USA. The conference featured a stellar line-up of domestic and international speakers and diverse participants including TNBC survivors, luminaries in breast cancer research, medical students and fellows, clinicians, translational researchers, epidemiologists, biostatisticians, bioinformaticians, and representatives from the industry. This report distills the burning questions that spiked the event and summarizes key themes, findings, unique opportunities and future directions that emerged from this confluence of thought leaders.

Keywords: Immunotherapy; Molecular subtypes; Racial disparities; Targeted drugs; Triple negative breast cancer.

PubMed Disclaimer

References

1. Dietze EC, Sistrunk C, Miranda-Carboni G, O’Regan R, Seewaldt VL. Triple-negative breast cancer in African-American women: disparities versus biology. Nature reviews Cancer. 2015;15(4):248–254. - PMC - PubMed
1. Pareja F, Geyer FC, Marchio C, Burke KA, Weigelt B, Reis-Filho JS. Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants. NPJ breast cancer. 2016;2:16036. - PMC - PubMed
1. Lehmann BD, Jovanović B, Chen X, Estrada MV, Johnson KN, Shyr Y, Moses HL, Sanders ME, Pietenpol JA. Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. PLOS ONE. 2016;11(6):e0157368. - PMC - PubMed
1. Masuda H, Baggerly KA, Wang Y, Zhang Y, Gonzalez-Angulo AM, Meric-Bernstam F, Valero V, Lehmann BD, Pietenpol JA, Hortobagyi GN, et al. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res. 2013;19(19):5533–5540. - PMC - PubMed
1. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. The Journal of clinical investigation. 2011;121(7):2750–2767. - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

First international TNBC conference meeting report

Affiliations

First international TNBC conference meeting report

Authors

Affiliations

Abstract

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources